Coherus BioSciences/$CHRS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Coherus BioSciences
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
Ticker
$CHRS
Sector
Primary listing
Employees
177
Headquarters
Website
CHRS Metrics
BasicAdvanced
$150M
0.83
$1.55
0.89
-
Price and volume
Market cap
$150M
Beta
0.89
52-week high
$1.77
52-week low
$0.66
Average daily volume
1.3M
Financial strength
Current ratio
1.442
Quick ratio
1.355
Long term debt to equity
32.775
Total debt to equity
34.24
Interest coverage (TTM)
-3.63%
Profitability
EBITDA (TTM)
-83.831
Gross margin (TTM)
55.79%
Net profit margin (TTM)
66.03%
Operating margin (TTM)
-32.50%
Revenue per employee (TTM)
$1,540,000
Management effectiveness
Return on assets (TTM)
-9.92%
Return on equity (TTM)
331.11%
Valuation
Price to earnings (TTM)
0.83
Price to revenue (TTM)
0.548
Price to book
1.25
Price to tangible book (TTM)
2.22
Price to free cash flow (TTM)
-1.26
Free cash flow yield (TTM)
-79.34%
Free cash flow per share (TTM)
-1.024
Growth
Revenue change (TTM)
52.33%
Earnings per share change (TTM)
-671.14%
3-year revenue growth (CAGR)
-0.48%
10-year revenue growth (CAGR)
22.69%
3-year earnings per share growth (CAGR)
-19.66%
10-year earnings per share growth (CAGR)
-12.22%
What the Analysts think about CHRS
Analyst ratings (Buy, Hold, Sell) for Coherus BioSciences stock.
CHRS Financial Performance
Revenues and expenses
CHRS Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Coherus BioSciences stock?
Coherus BioSciences (CHRS) has a market cap of $150M as of September 14, 2025.
What is the P/E ratio for Coherus BioSciences stock?
The price to earnings (P/E) ratio for Coherus BioSciences (CHRS) stock is 0.83 as of September 14, 2025.
Does Coherus BioSciences stock pay dividends?
No, Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders as of September 14, 2025.
When is the next Coherus BioSciences dividend payment date?
Coherus BioSciences (CHRS) stock does not pay dividends to its shareholders.
What is the beta indicator for Coherus BioSciences?
Coherus BioSciences (CHRS) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.